At the presentation of the Pharming Group N.V. preliminary (unaudited) financial report for the first six months of 2021, CEO Sijmen de Vries comments:
“Post period, we delivered on one of our strategic objectives to strengthen our longer-term HAE pipeline, through a collaboration with Orchard Therapeutics, to develop and commercialize the pre-clinical ex-vivo autologous hematopoietic stem cell therapy product OTL-105, which has the potential to become a curative treatment for HAE. We remain focused on the positive progress against our three-pillar strategy of sales, R&D and acquisitive growth.”
(Source: Pharming)
